the subcutaneous inoculation of 16 white mice and 10 golden hamsters with l.tropica major resulted in the development of leishmanial lesions in all, becoming generalized in some.two of 10 hamsters inoculated intraperitoneally with this parasite developed generalized lesions. on the other hand, the inoculation of l. tropica minor to 128 mice subcutaneously and 170 mice intraperitoneally did not ...

Inhibition of the Tryparedoxin peroxidase interaction has been becomes a new therapeutic strategy in leishmaniasis. Docking analysis was carried out to study the effects of quercetin and taxifolin on Tryparedoxin Peroxidase (TryP). Tryparedoxin peroxidase of Trypanosomatidae functions as antioxidants through their Peroxidase and peroxynitrite reductase activities. The 3D models of Tryparedoxin ...

Objectives We examined the in vitro pharmacodynamics and cellular accumulation of the standard anti-leishmanial drugs amphotericin B and miltefosine in intracellular Leishmania donovani amastigote-macrophage drug assays. Methods Primary mouse macrophages were infected with L. donovani amastigotes. In time-kill assays infected macrophages were exposed to at least six different concentrations o...

Despite advances, identification and formulation of safe and effective vaccine for long-lasting protection against leishmaniasis is still inadequate. In this study, we have identified a novel antigen, leishmanial elongation factor-1α (EF1-α), as an immunodominant component of solubilized leishmanial membrane antigens that reacts with visceral leishmaniasis (VL) sera and induces cellular prolife...

Leishmaniasis comprises an array of diseases caused by pathogenic species of Leishmania, resulting in a spectrum of mild to life-threatening pathologies. Currently available therapies for leishmaniasis include a limited selection of drugs. This coupled with the rather fast emergence of parasite resistance, presents a dire public health concern. Paromomycin (PAR), a broad-spectrum aminoglycoside...

Leishmaniasis is one of the world's most neglected diseases, largely affecting the poorest of the poor, mainly in developing countries. Over 350 million people are considered at risk of contracting leishmaniasis, and approximately 2 million new cases occur yearly(1). Leishmania donovani is the causative agent for visceral leishmaniasis (VL), the most fatal form of the disease. The choice of dru...

Post Kala Azar Dermal Leishmaniasis (PKDL) is an unusual dermatosis caused by a parasite Leishmania donovani (LD). It occurs between six months and five years of following an attack of Visceral Leishmaniasis (VL) / Kala Azar (KA). As a recurrence of VL, it keeps appearing on the skin of patient even after 20 years of partial treatment, inadequate treatment and in untreated cases. We here 4 case...

cutaneous leishmaniasis is endemic in 88 different countries. there are an estimated 1.5 million new cases each year, with over 90% occurring in afghanistan, algeria, iran, iraq, saudi arabia, syria (old world) and in brazil and peru (new world). miltefosine is effective in vitro and in vivo against leishmania species and it was demonstrated efficacy in animals via the oral route. this study is...